CO2018001599A2 - Un inhibidor de anticuerpo monoclonal de factor xiia - Google Patents
Un inhibidor de anticuerpo monoclonal de factor xiiaInfo
- Publication number
- CO2018001599A2 CO2018001599A2 CONC2018/0001599A CO2018001599A CO2018001599A2 CO 2018001599 A2 CO2018001599 A2 CO 2018001599A2 CO 2018001599 A CO2018001599 A CO 2018001599A CO 2018001599 A2 CO2018001599 A2 CO 2018001599A2
- Authority
- CO
- Colombia
- Prior art keywords
- monoclonal antibody
- factor xiia
- antibody inhibitor
- diseases
- factor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
Acá se divulgan anticuerpos anti-Factor XIIa y método para usar los mismos para el tratamiento de enfermedades asociadas con Factor XII, incluyendo enfermedades asociadas con activación de sistema de contacto, señalización de precalicreína de plasma (por ejemplo, angioedema hereditario), y enfermedades oculares.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562194957P | 2015-07-21 | 2015-07-21 | |
US201562273657P | 2015-12-31 | 2015-12-31 | |
US201662316310P | 2016-03-31 | 2016-03-31 | |
PCT/US2016/043265 WO2017015431A1 (en) | 2015-07-21 | 2016-07-21 | A monoclonal antibody inhibitor of factor xiia |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2018001599A2 true CO2018001599A2 (es) | 2018-05-10 |
Family
ID=56555827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2018/0001599A CO2018001599A2 (es) | 2015-07-21 | 2018-02-19 | Un inhibidor de anticuerpo monoclonal de factor xiia |
Country Status (15)
Country | Link |
---|---|
US (2) | US10913802B2 (es) |
EP (2) | EP4011916A1 (es) |
JP (3) | JP7068160B2 (es) |
KR (1) | KR20180096567A (es) |
CN (2) | CN108137705B (es) |
AU (2) | AU2016297018B9 (es) |
BR (1) | BR112018001202A2 (es) |
CA (1) | CA2993026A1 (es) |
CO (1) | CO2018001599A2 (es) |
EA (1) | EA201890340A1 (es) |
HK (1) | HK1255423A1 (es) |
IL (1) | IL257047A (es) |
MX (2) | MX2018000714A (es) |
NZ (1) | NZ739088A (es) |
WO (1) | WO2017015431A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ733580A (en) | 2015-01-02 | 2024-02-23 | Takeda Pharmaceuticals Co | Bispecific antibodies against plasma kallikrein and factor xii |
MX2018000714A (es) | 2015-07-21 | 2019-11-18 | Dyax Corp | Un inhibidor de anticuerpo monoclonal de factor xiia. |
CN109260462B (zh) * | 2018-08-24 | 2021-05-11 | 上海交通大学医学院附属瑞金医院 | 一种凝血酶原突变体蛋白及其编码核酸的应用 |
AU2020396054A1 (en) * | 2019-12-03 | 2022-07-07 | CSL Innovation Pty Ltd | Use of an anti-Factor XII antibody for the treatment or prevention of hereditary angioedema |
CN117487017A (zh) * | 2020-07-02 | 2024-02-02 | 北京拓界生物医药科技有限公司 | 抗FXI/FXIa抗体、其抗原结合片段及医药用途 |
KR20230035355A (ko) * | 2020-07-03 | 2023-03-13 | 씨에스엘 이노베이션 피티와이 엘티디 | 인자 xii 항원 결합 단백질의 고농도 제형 |
US20230390418A1 (en) * | 2020-10-29 | 2023-12-07 | Regenxbio Inc. | Vectorized factor xii antibodies and administration thereof |
JP2024513244A (ja) * | 2021-04-07 | 2024-03-22 | ミシク セラピューティクス, インコーポレイテッド | 抗原結合タンパク質構築物および抗体およびその使用 |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
US4963657A (en) | 1988-06-09 | 1990-10-16 | Temple University Of The Commonwealth System Of Higher Education | Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same |
WO1990007936A1 (en) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
US5500349A (en) | 1989-01-27 | 1996-03-19 | Coagen Limited | Blood-coagulation factor XIIA β monoclonal antibody and immunoassay |
GB8901859D0 (en) | 1989-01-27 | 1989-03-15 | Shield Diagnostics Limited | Diagnostic test |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
ES2200016T3 (es) | 1989-03-21 | 2004-03-01 | Vical Incorporated | Expresion de secuencias polinucleotidicas exogenas en un vertebrado. |
EP1001032A3 (en) | 1989-08-18 | 2005-02-23 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
WO1991017258A1 (en) | 1990-05-10 | 1991-11-14 | Cetus Corporation | Inhibitors of factor xii activation and applications thereof |
JP3534749B2 (ja) | 1991-08-20 | 2004-06-07 | アメリカ合衆国 | アデノウイルスが介在する胃腸管への遺伝子の輸送 |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
JPH07507689A (ja) | 1992-06-08 | 1995-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 特定組織のターゲティング方法及び組成物 |
WO1993025698A1 (en) | 1992-06-10 | 1993-12-23 | The United States Government As Represented By The | Vector particles resistant to inactivation by human serum |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
AU680459B2 (en) | 1992-12-03 | 1997-07-31 | Genzyme Corporation | Gene therapy for cystic fibrosis |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
WO1994023697A1 (en) | 1993-04-22 | 1994-10-27 | Depotech Corporation | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
ES2249761T3 (es) | 1993-06-24 | 2006-04-01 | Advec Inc. | Vectores de adenovirus para terapia genica. |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
CA2523216C (en) | 1993-09-15 | 2010-11-16 | Chiron Corporation | Recombinant alphavirus vectors |
DK0797676T3 (da) | 1993-10-25 | 2006-04-18 | Canji Inc | Rekombinant adenoviral vektor og fremgangsmåder til anvendelse deraf |
CA2176712C (en) | 1993-11-16 | 2000-05-23 | Mantripragada Sankaram | Synthetic membrane vesicles with controlled release of encapsulated biologically active substances |
DE69535669T2 (de) | 1994-05-09 | 2008-12-04 | Oxford Biomedica (Uk) Ltd. | Retrovirale vektoren mit verminderter rekombinationsrate |
WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
GB9609262D0 (en) | 1996-05-02 | 1996-07-03 | Isis Innovation | Peptide library and method |
ATE424463T1 (de) | 1996-05-06 | 2009-03-15 | Oxford Biomedica Ltd | Rekombinationsunfähige retrovirale vektoren |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
AU3734900A (en) | 1999-03-09 | 2000-09-28 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
CA2591786C (en) | 2004-12-23 | 2013-07-16 | Bernhard Nieswandt | Prevention of thrombus formation and/or stabilization |
GB0500487D0 (en) * | 2005-01-11 | 2005-02-16 | Axis Shield Diagnostics Ltd | Forms of factor XIIa |
US7932021B2 (en) | 2005-07-28 | 2011-04-26 | American Diagnostica, Inc. | Lupus anticoagulant testing |
GB0607515D0 (en) | 2006-04-13 | 2006-05-24 | Axis Shield Diagnostics Ltd | Anti-factor xlla therapy |
TWI465247B (zh) * | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子vii多肽和其用途 |
TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之egfr/igfir結合分子 |
SI2521568T1 (sl) | 2010-01-06 | 2019-01-31 | Dyax Corp. | Proteini, ki vežejo plazemski kalikrein |
CN103635489B (zh) | 2011-01-06 | 2016-04-13 | 戴埃克斯有限公司 | 血浆前激肽释放酶结合蛋白 |
JP6253578B2 (ja) | 2011-07-22 | 2017-12-27 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 阻害性抗第xii/xiia因子モノクローナル抗体及びそれらの使用 |
JP5653860B2 (ja) | 2011-07-28 | 2015-01-14 | 富士フイルム株式会社 | 管壁の硬度測定方法および装置 |
JP6271251B2 (ja) | 2011-10-05 | 2018-01-31 | 中外製薬株式会社 | 糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子 |
CA2859667C (en) | 2011-12-20 | 2022-05-24 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
WO2014019644A1 (en) | 2012-07-31 | 2014-02-06 | Baxter International Inc. | Selective measurement of active human protease coagulation factors |
US9574013B2 (en) * | 2012-12-07 | 2017-02-21 | Vanderbilt University | Antibodies against factor XII and uses thereof |
PL2946206T3 (pl) | 2013-01-20 | 2019-07-31 | Dyax Corp. | Ocena, testy i leczenie zaburzeń mediowanych przez PKAL |
CN105051068A (zh) | 2013-03-15 | 2015-11-11 | 戴埃克斯有限公司 | 抗血浆激肽释放酶抗体 |
US20160166660A1 (en) | 2013-06-28 | 2016-06-16 | Csl Behring Gmbh | Combination therapy using a factor xii inhibitor and a c-1 inhibitor |
HRP20220553T1 (hr) | 2013-07-25 | 2022-06-10 | Cytomx Therapeutics Inc. | Polispecifična protutijela, polispecifična protutijela koja se mogu aktivirati i postupci uporabe navedenih protutijela |
NZ733580A (en) | 2015-01-02 | 2024-02-23 | Takeda Pharmaceuticals Co | Bispecific antibodies against plasma kallikrein and factor xii |
MX2018000714A (es) * | 2015-07-21 | 2019-11-18 | Dyax Corp | Un inhibidor de anticuerpo monoclonal de factor xiia. |
-
2016
- 2016-07-21 MX MX2018000714A patent/MX2018000714A/es unknown
- 2016-07-21 CN CN201680046558.0A patent/CN108137705B/zh active Active
- 2016-07-21 BR BR112018001202A patent/BR112018001202A2/pt active Search and Examination
- 2016-07-21 AU AU2016297018A patent/AU2016297018B9/en active Active
- 2016-07-21 JP JP2018501883A patent/JP7068160B2/ja active Active
- 2016-07-21 KR KR1020187005024A patent/KR20180096567A/ko not_active Application Discontinuation
- 2016-07-21 WO PCT/US2016/043265 patent/WO2017015431A1/en active Application Filing
- 2016-07-21 CN CN202211273734.8A patent/CN116333144A/zh active Pending
- 2016-07-21 NZ NZ739088A patent/NZ739088A/en unknown
- 2016-07-21 US US15/746,048 patent/US10913802B2/en active Active
- 2016-07-21 EP EP21204197.4A patent/EP4011916A1/en active Pending
- 2016-07-21 EP EP16745341.4A patent/EP3325516B1/en active Active
- 2016-07-21 EA EA201890340A patent/EA201890340A1/ru unknown
- 2016-07-21 CA CA2993026A patent/CA2993026A1/en active Pending
-
2018
- 2018-01-17 MX MX2023006511A patent/MX2023006511A/es unknown
- 2018-01-21 IL IL257047A patent/IL257047A/en unknown
- 2018-02-19 CO CONC2018/0001599A patent/CO2018001599A2/es unknown
- 2018-11-15 HK HK18114586.1A patent/HK1255423A1/zh unknown
-
2020
- 2020-12-29 US US17/136,483 patent/US20210230299A1/en active Pending
-
2021
- 2021-05-19 JP JP2021084554A patent/JP7317891B2/ja active Active
-
2022
- 2022-11-10 AU AU2022268373A patent/AU2022268373A1/en active Pending
-
2023
- 2023-07-19 JP JP2023117873A patent/JP2023145564A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2022268373A1 (en) | 2022-12-15 |
CN108137705B (zh) | 2022-11-08 |
JP7317891B2 (ja) | 2023-07-31 |
JP2023145564A (ja) | 2023-10-11 |
EA201890340A1 (ru) | 2018-09-28 |
EP3325516A1 (en) | 2018-05-30 |
US20210230299A1 (en) | 2021-07-29 |
JP7068160B2 (ja) | 2022-05-16 |
IL257047A (en) | 2018-03-29 |
KR20180096567A (ko) | 2018-08-29 |
EP4011916A1 (en) | 2022-06-15 |
CN116333144A (zh) | 2023-06-27 |
JP2021121615A (ja) | 2021-08-26 |
MX2023006511A (es) | 2023-06-21 |
HK1255423A1 (zh) | 2019-08-16 |
US20190002584A1 (en) | 2019-01-03 |
WO2017015431A1 (en) | 2017-01-26 |
MX2018000714A (es) | 2019-11-18 |
BR112018001202A2 (pt) | 2018-09-25 |
CN108137705A (zh) | 2018-06-08 |
AU2016297018B2 (en) | 2022-08-11 |
WO2017015431A8 (en) | 2017-03-23 |
AU2016297018B9 (en) | 2022-12-01 |
CA2993026A1 (en) | 2017-01-26 |
JP2018520684A (ja) | 2018-08-02 |
NZ739088A (en) | 2024-01-26 |
US10913802B2 (en) | 2021-02-09 |
EP3325516B1 (en) | 2021-12-15 |
AU2016297018A1 (en) | 2018-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018001599A2 (es) | Un inhibidor de anticuerpo monoclonal de factor xiia | |
BR112017007170A2 (pt) | anticorpos anti-ox40 humanizados e suas utilizações | |
CR20170131A (es) | Anticuerpos anti-her2 e inmunoconjugados | |
CR20170026A (es) | Anticuerpos anti-tau humanizados | |
CR20180013A (es) | Anticuerpos anti-tau y métodos de uso. | |
CL2019001554S1 (es) | Automóvil. | |
BR112019012343A2 (pt) | anticorpos il-11ra | |
CR20190271A (es) | Anticuerpos antitau y métodos de uso | |
MX2019011423A (es) | Metodos de tratamiento de enfermedades neurodegenerativas. | |
BR112017022838A2 (pt) | receptores quiméricos de antígeno de antígenos de mieloma kappa e seus usos | |
CY1124521T1 (el) | Σκευασματα αντισωματος anti-cd19 | |
CR20160270A (es) | ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN | |
EA201991818A1 (ru) | Лечение рака | |
EA202091989A1 (ru) | Способы лечения язвенного колита | |
CU24556B1 (es) | Anticuerpos anti-basigin humanizados | |
EA201891628A1 (ru) | Ингибирование аллергической реакции с использованием ингибитора il-33 | |
BR112021014944A2 (pt) | Toxinas apxia, apxiia e apxiiia inativas | |
EA201991876A1 (ru) | Антитела против фактора d и их применения | |
CL2019002232S1 (es) | Automóvil. | |
CO2022009696A2 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
CL2020001201S1 (es) | Automóvil. | |
CL2020000174S1 (es) | Automóvil. | |
EA201990253A1 (ru) | Гуманизированные антитела против s100a9 и их применение | |
AR105595A1 (es) | PROCEDIMIENTO PARA EL TRATAMIENTO DE ENFERMEDADES INFECCIOSAS UTILIZANDO UNA COMPOSICIÓN QUE COMPRENDE INMUNOGLOBULINA M (IgM) DERIVADA DE PLASMA | |
CL2020000224S1 (es) | Automóvil. |